10.10
3.61%
-0.44
アフターアワーズ:
10.10
Y Mabs Therapeutics Inc (YMAB) 最新ニュース
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2024 Earnings Call Transcript - MSN
Oppenheimer Begins Coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World
Y-mAbs started at outperform at Oppenheimer on pre-targeted radiotherapies - MSN
The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26% - Simply Wall St
Brain Cancer Treatment Market Growth Overview Future - openPR
Y-mAbs Therapeutics (NASDAQ:YMAB) Now Covered by Analysts at Oppenheimer - MarketBeat
Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock - Benzinga
Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics' (YMAB) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Trading (YMAB) With Integrated Risk Controls - Stock Traders Daily
YMAB FY2024 EPS Forecast Increased by Cantor Fitzgerald - Defense World
Asia Deal Watch: Apollo Takes A Shine To Chinese Biotech’s Cardiometabolic Candidate - Scrip
Cantor Fitzgerald Issues Positive Outlook for YMAB Earnings - MarketBeat
Investors might be losing patience for Y-mAbs Therapeutics' (NASDAQ:YMAB) increasing losses, as stock sheds 13% over the past week - Simply Wall St
Leptomeningeal Metastases Clinical Trials 2024: FDA - openPR
Y-mAbs Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate DevelopmentsY-mAbs Therapeutics, a biopharmaceutical company focusing on innovative radioimmunotherapy and antibody-based products for cancer treatment, rec - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down After Earnings Miss - Defense World
Earnings call: Y-mAbs Therapeutics reports Q3 2024 financials - Investing.com India
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates - MSN
Y-mAbs Therapeutics (NASDAQ:YMAB) Issues Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... By GuruFocus - Investing.com Canada
Y-mAbs Therapeutics Inc (YMAB) Quarterly 10-Q Report - Quartzy
Y-mAbs Reports Third Quarter 2024 Financial Results - TipRanks
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap DownShould You Sell? - MarketBeat
Y-mAbs Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2024 - Marketscreener.com
Y mAbs Therapeutics earnings missed by $0.01, revenue fell short of estimates - Investing.com Canada
Y-mAbs Therapeutics Inc Reports Q3 2024 Revenue of $18.5 Million - GuruFocus.com
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments - The Manila Times
Y-mAbs Q3 Revenue Falls 10%, But Secures Key Japan Deal and Patent Extension | YMAB Stock News - StockTitan
Examining the Future: Y-mAbs Therapeutics's Earnings Outlook - Benzinga
What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earni - GuruFocus.com
What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings - Yahoo Finance
Exclusive License Agreement Between Y-mAbs Therapeutics, Inc. and Nobelpharma Co., Ltd. for Development and Commercialization of DANYELZA(R) in Japan - Defense World
(YMAB) Trading Advice - Stock Traders Daily
Vanguard Group Inc's Strategic Acquisition in Y-mAbs Therapeutics Inc - GuruFocus.com
Y-mAbs enters Japan market with Nobelpharma for cancer therapy By Investing.com - Investing.com Canada
Y-mAbs enters Japan market with Nobelpharma for cancer therapy - Investing.com
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan - The Manila Times
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates - MSN
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know - MSN
Y-mAbs Therapeutics (YMAB) Scheduled to Post Quarterly Earnings on Friday - Defense World
Y-mAbs Therapeutics (YMAB) Scheduled to Post Earnings on Friday - MarketBeat
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights - Benzinga
Y-mAbs Therapeutics Investors Get Final OK For $19.7M Deal - Law360
Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Objective long/short (YMAB) Report - Stock Traders Daily
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast - The Manila Times
Y-Mabs Therapeutics Inc (YMAB-Q) QuotePress Release - The Globe and Mail
13,566 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Bought by SG Americas Securities LLC - Defense World
Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers (NASDAQ:YMAB) - Seeking Alpha
AQR Capital Management LLC Makes New Investment in TreeHouse Foods, Inc. (NYSE:THS) - Defense World
Cubist Systematic Strategies LLC Has $80,000 Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
大文字化:
|
ボリューム (24 時間):